Ironwood Pharmaceuticals Inc IRWD
Ironwood Pharmaceuticals Inc (Nasdaq: IRWD) is a GI/hepatology drug developer. Its lead program, apraglutide, is in Phase 3 for Short bowel syndrome dependent on parenteral support.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| LINZESS (linaclotide) | IBS-C / CIC | protein/peptide | Approved |
| apraglutide | short bowel syndrome | protein/peptide | Phase 3 |
Recent results and decisions
- Jan 1, 2027n/a Tammi Gaskins appointed Chief Executive Officer effective January 1, 2027, succeeding Tom McCourt who will retire after 17 years at Ironwood.
The Board of Directors selected Tammi Gaskins to be Ironwood's next CEO because she is a proven leader with a deep understanding of the business, culture and late-stage pipeline.
Filing - Oct 12, 2026n/a Ironwood Pharmaceuticals appoints Tammi Gaskins as Chief Executive Officer effective January 1, 2027, succeeding Tom McCourt who will retire after 17 years.
The Board of Directors selected Tammi Gaskins to be Ironwood's next CEO because she is a proven leader with a deep understanding of the business, culture and late-stage pipeline.
Filing - Aug 6, 2026started Confirmatory Phase 3 STARS-2 of apraglutide initiated and actively recruiting (24-week randomized placebo-controlled; primary endpoint relative change in weekly parenteral support volume).
Confirmatory Phase 3 STARS-2 trial of apraglutide in short bowel syndrome with intestinal failure (SBS-IF) now actively recruiting patients
Filing
4 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 GI/hepatology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.